RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Daito Pharmaceutical Co Stock

Daito Pharmaceutical Co P/E 2024

Daito Pharmaceutical Co P/E

10.67

Ticker

4577.T

ISIN

JP3486150000

WKN

A1CXXT

As of Sep 26, 2024, Daito Pharmaceutical Co's P/E ratio was 10.67, a 17.9% change from the 9.05 P/E ratio recorded in the previous year.

The Daito Pharmaceutical Co P/E history

Daito Pharmaceutical Co Aktienanalyse

What does Daito Pharmaceutical Co do?

Daito Pharmaceutical Co Ltd is a Japanese pharmaceutical company that was founded in 1947. The company is headquartered in Osaka and is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Daito Pharmaceutical specializes in the development and manufacturing of medications and has a strong presence in the East Asia region. History: Daito Pharmaceutical was founded by Masaharu Imai, a pharmacist driven by the idea of producing medications that would help people and alleviate suffering. The company started as a small family business, producing a limited number of medications in a workshop in Osaka. Some of the earliest products were injection solutions and ready-to-use medications. In the 1950s, Daito Pharmaceutical expanded its product range and began developing medications for chronic diseases such as diabetes and heart diseases. The company also expanded geographically and started selling its products in other parts of Japan. In the following years, Daito Pharmaceutical expanded its capabilities and presence through mergers and acquisitions. One of the most significant acquisitions was the acquisition of Union Chemical Industry Co Ltd in 1973. This acquisition expanded Daito Pharmaceutical's portfolio with new products and technologies, as well as customers and distribution channels in other countries. Business model: Daito Pharmaceutical is a company that focuses on the development, manufacturing, and marketing of prescription and OTC medications. The company is divided into several business units that specialize in specific therapeutic areas. One of Daito Pharmaceutical's largest business units is the oncology division. Here, the company works on developing new cancer medications and supports doctors in the treatment of patients with cancer. Another business unit is the neurology division, which focuses on the development of medications for the treatment of neurological disorders such as Alzheimer's and Parkinson's. Products: Daito Pharmaceutical offers a wide range of medications that can be used for a variety of conditions. The company's products are divided into various therapy areas, including cardiology, oncology, neurology, and gastroenterology. An example of a Daito Pharmaceutical product is Nazastat (Nafazaon), a medication used for the treatment of type 2 diabetes. It is administered orally and works by inhibiting glucose production in the liver and improving insulin sensitivity in muscle and fat tissues. Another product of Daito Pharmaceutical is Tegosept (Methisazin), a medication used for the treatment of upper respiratory tract infections such as sinusitis and pharyngitis. The medication is administered orally and works by inhibiting the growth of bacteria such as Streptococcus and Staphylococcus. Conclusion: Daito Pharmaceutical Co Ltd is a Japanese pharmaceutical company that specializes in the development, manufacturing, and marketing of medications. The company has a long history in the industry and has expanded its capabilities and presence over the years through mergers and acquisitions. Daito Pharmaceutical has several business units specializing in different therapeutic areas, including oncology, neurology, and cardiology. The company offers a wide range of medications that can be used for a variety of conditions. Daito Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Daito Pharmaceutical Co's P/E Ratio

The Price to Earnings (P/E) Ratio of Daito Pharmaceutical Co is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Daito Pharmaceutical Co's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Daito Pharmaceutical Co is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Daito Pharmaceutical Co’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Daito Pharmaceutical Co stock

What is the price-to-earnings ratio of Daito Pharmaceutical Co?

The price-earnings ratio of Daito Pharmaceutical Co is currently 10.67.

How has the price-earnings ratio of Daito Pharmaceutical Co changed compared to last year?

The price-to-earnings ratio of Daito Pharmaceutical Co has increased by 17.9% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Daito Pharmaceutical Co high compared to other companies?

Yes, the price-to-earnings ratio of Daito Pharmaceutical Co is high compared to other companies.

How does an increase in the price-earnings ratio of Daito Pharmaceutical Co affect the company?

An increase in the price-earnings ratio of Daito Pharmaceutical Co would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Daito Pharmaceutical Co affect the company?

A decrease in the price-earnings ratio of Daito Pharmaceutical Co would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Daito Pharmaceutical Co?

Some factors that influence the price-earnings ratio of Daito Pharmaceutical Co are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Daito Pharmaceutical Co pay?

Over the past 12 months, Daito Pharmaceutical Co paid a dividend of 65 JPY . This corresponds to a dividend yield of about 2.83 %. For the coming 12 months, Daito Pharmaceutical Co is expected to pay a dividend of 70.35 JPY.

What is the dividend yield of Daito Pharmaceutical Co?

The current dividend yield of Daito Pharmaceutical Co is 2.83 %.

When does Daito Pharmaceutical Co pay dividends?

Daito Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of December, June, December, June.

How secure is the dividend of Daito Pharmaceutical Co?

Daito Pharmaceutical Co paid dividends every year for the past 18 years.

What is the dividend of Daito Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 70.35 JPY are expected. This corresponds to a dividend yield of 3.07 %.

In which sector is Daito Pharmaceutical Co located?

Daito Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Daito Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Daito Pharmaceutical Co from 2/1/2025 amounting to 35 JPY, you needed to have the stock in your portfolio before the ex-date on 11/28/2024.

When did Daito Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 2/1/2025.

What was the dividend of Daito Pharmaceutical Co in the year 2023?

In the year 2023, Daito Pharmaceutical Co distributed 60 JPY as dividends.

In which currency does Daito Pharmaceutical Co pay out the dividend?

The dividends of Daito Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Daito Pharmaceutical Co

Our stock analysis for Daito Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Daito Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.